Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Neda Stjepanovic, Jaume CapdevilaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, SpainAbstract: Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are...
Guardado en:
Autores principales: | Stjepanovic N, Capdevila J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f48bfc139a3143eab3a20b5125564756 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez CA, et al.
Publicado: (2012) -
Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim S, et al.
Publicado: (2014) -
Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
por: Soji Toda, et al.
Publicado: (2021) -
Role of vandetanib in the management of medullary thyroid cancer
por: Rondeau G, et al.
Publicado: (2012) -
Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Bernadette Biondi, et al.
Publicado: (2008)